In a Series B financing round, INSERM spin-off Acticor Biotech has raised €15.3m from European and Asian investors. The new financing will go towards the launch off the first Phase II clinical trial of its lead candidate ACT017 in acute ischemic stroke. 

Multinational biotherapeutics company HiFiBiO Therapeutics announced that it has taken over early stage biotech H-Immune Therapeutics. With the acquisition of the French Atomic Energy Commission spin-out, HiFiBiO aims to strengthen its strategic focus on targetting differenct T cell subsets and combat cancer. 

Roche has announced that in a Phase III trial, its antibody-drug conjugate Kadcyla showed improved invasive disease-free survival in breast cancer patients.

Is synthetic biology on the cusp of unlocking the next industrial revolution? A major roadblock is the ability to synthesise DNA for R&D in ways that are both cheap and efficient. Established players in the field believe the answer lies in miniaturising standard chemical processes and running them in parallel systems. But the new kids on the block are betting on a completely new process that involves enzymes.

Targovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer.

The demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered the cell line kit CHOvolution, which equips users with everything required for the development of mammalian cell lines and provides an integrated support system for assistance.

Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.  

T cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).

Genentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I trails. 

Aglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.